Grifols SA (GRFS)
7.34
+0.14
(+1.94%)
USD |
NASDAQ |
Sep 25, 16:00
7.34
0.00 (0.00%)
After-Hours: 19:59
Grifols Research and Development Expense (Annual) : 420.96M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 420.96M |
| December 31, 2024 | 357.74M |
| December 31, 2023 | 357.36M |
| December 31, 2022 | 333.00M |
| December 31, 2021 | 354.09M |
| December 31, 2020 | 297.99M |
| December 31, 2019 | 283.78M |
| December 31, 2018 | 260.52M |
| Date | Value |
|---|---|
| December 31, 2017 | 251.23M |
| December 31, 2016 | 204.17M |
| December 31, 2015 | 233.47M |
| December 31, 2014 | 222.44M |
| December 31, 2013 | 147.70M |
| December 31, 2012 | 147.39M |
| December 31, 2011 | 106.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| argenx SE | 1.356B |
| Evaxion AS | 9.691M |
| Autolus Therapeutics Plc | 128.59M |
| Pharma Mar SA | 104.94M |
| Oryzon Genomics SA | 14.22M |